


Stabilis



Cefotaxime sodium



Tradename

Alvim	Mexico
Antadar	Portugal
Aximad	Italy
Batixim	Italy
Betaksim	Turkey
Biotaksym	Poland
Cefacolin	Argentina
Cefotax	Brazil, Romania
Cefotaxim	Germany
Ceftax	Saudi Arabia
Centiax	Italy
Claforan	Austria, Belgium, Brazil, Canada, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Luxembourg, Morocco, Netherlands, Saudi Arabia, Spain, United Arab Emirates, United States of America, Venezuela
Clafotax	Saudi Arabia
Foxim	Saudi Arabia
Letynol	Greece
Lirgosin	Italy
Molelant	Greece
Naspor	Greece
Phacocef	Greece
Primocef	Saudi Arabia
Rantaksyn	Poland
Refotax	Italy
Salocef	Italy
Sefotak	Turkey
Spectrocef	Italy
Spirosine	Greece
Stoparen	Greece
Tarcefoksym	Poland
Taxocef	Turkey
Tirotax	Poland
Totam	Republic of South Africa, Saudi Arabia
Zariviz	Italy



Stability in solutions

		20 mg/ml	24°C		24			421
		20 mg/ml	2-8°C		24			1452
		20 mg/ml	25°C		24			1452
		10 mg/ml	-10°C		112			593
		10 mg/ml	24°C		24			593
		10 mg/ml	4°C		22			593
		20 mg/ml	24°C		24			421
		10 mg/ml	-20°C		90			592
		10 mg/ml	25°C		24			592
		10 mg/ml	4°C		4			592
		0,86 mg/ml	37°C		6			2374
		0,92 mg/ml	25°C		24			2374
		0,80 mg/ml	37°C		6			2374
		0,87 mg/ml	25°C		24			2374
		20 mg/ml	2-8°C		24			1452
		20 mg/ml	25°C		24			1452
		125 mg/ml	20-25°C		6			4268
		83,3 mg/ml	20-25°C		6			4268
		50 mg/ml	25°C		24			1711
		50 mg/ml	5°C		18			1711
		5 & 40 mg/ml	25°C		24			604



Stability of mixtures

		20 mg/ml	24°C		Clindamycin phosphate : 9 mg/ml	24		421
		20 mg/ml	24°C		Clindamycin phosphate : 9 mg/ml	24		421
		10 mg/ml	28°C		Metronidazole : 5 mg/ml	12		281
		10 mg/ml	5°C		Metronidazole : 5 mg/ml	96		281
		5 mg/ml	20°C		Tinidazole : 2 mg/ml	8		2185



Factors which affect stability

4,5 < pH < 5,5			592
----------------	--	--	-----



Compatibility

		Cefotaxime sodium : 20 mg/ml Allopurinol sodium : 3 mg/ml		307
		Cefotaxime sodium : 20 mg/ml		1415
		Cefotaxime sodium : 20 mg/ml Aciclovir sodium : 5 mg/ml		336
		Cefotaxime sodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Cefotaxime sodium Amphotericin B		3871
		Cefotaxime sodium : 200 mg/ml Azithromycine : 2 mg/ml		1800
		Cefotaxime sodium : 100 mg/ml Caffeine : 10 mg/ml		4837
		Cefotaxime sodium : 40 mg/ml		4832
		Cefotaxime sodium : 100 mg/ml Alprostadil : 15 µg/ml		3201
		Cefotaxime sodium : 100 mg/ml	RL	4603
		Cefotaxime sodium : 20 mg/ml Amifostine : 10 mg/ml		3
		Cefotaxime sodium Amikacin sulfate		3549
		Cefotaxime sodium : 40 mg/ml Amiodarone hydrochloride : 9 mg/ml		4698
		Cefotaxime sodium : 20 mg/ml Aztreonam : 40 mg/ml		99
		Cefotaxime sodium : 20 mg/ml Bivalirudin : 5 mg/ml		1713
		Cefotaxime sodium : 100 mg/ml Caffeine : 10 mg/ml		3964
		Cefotaxime sodium : 100 mg/ml Caffeine citrate : 20 mg/ml		4837
		Cefotaxime sodium : 20 mg/ml Cisatracurium besylate : 5 mg/ml		299
		Cefotaxime sodium : 20 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
		Cefotaxime sodium : 20 mg/ml Cisatracurium besylate : 2 mg/ml		299
		Cefotaxime sodium : 60 mg/ml		316
		Cefotaxime sodium : 95 mg/ml Cloxacillin sodium : 100 mg/ml		3012

		Cefotaxime sodium : 20 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Cefotaxime sodium : 40 mg/ml		4832
		Cefotaxime sodium : 20 mg/ml Clindamycin phosphate : 9 mg/ml		421
		Cefotaxime sodium Clindamycin phosphate		3526
		Cefotaxime sodium : 10 & 180 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Cefotaxime sodium Dimenhydrinate		2087
		Cefotaxime sodium : 20 mg/ml Docetaxel : 0.9 mg/ml		1754
		Cefotaxime sodium Erythromycin lactobionate		3674
		Cefotaxime sodium : 20 mg/ml		301
		Cefotaxime sodium : 20 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Cefotaxime sodium : 20 mg/ml Famotidine		397
		Cefotaxime sodium : 20 mg/ml Famotidine : 2 mg/ml		215
		Cefotaxime sodium : 200 mg/ml		939
		Cefotaxime sodium : 20 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Cefotaxime sodium : 20 mg/ml Fentanyl citrate : 50 µg/ml		63
		Cefotaxime sodium : 20 mg/ml Filgrastim : 30 µg/ml		244
		Cefotaxime sodium : 20 mg/ml Fluconazole : 2 mg/ml		496
		Cefotaxime sodium : 20 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Cefotaxime sodium : 20 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Cefotaxime sodium Gentamicin sulfate		3643
		Cefotaxime sodium Gentamicin sulfate		3520
		Cefotaxime sodium : 20 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Cefotaxime sodium : 10 mg/ml Heparin sodium : 5000 UI/ml		3125
		Cefotaxime sodium : 41.6 & 125 mg/ml Heparin sodium : 208 UI/ml		4254
		Cefotaxime sodium : 20 mg/ml Hetastarch : 60 mg/ml		472
		Cefotaxime sodium : 20 mg/ml Hetastarch : 60 mg/ml		1721
		Cefotaxime sodium : 83.3 mg/ml Hydrocortisone sodium succinate : 2 mg/ml		4254

	Cefotaxime sodium : 20 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
	Cefotaxime sodium : 83.3 mg/ml Insulin : 1 UI/ml		4254
	Cefotaxime sodium : 100 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
	Cefotaxime sodium : 83.3 mg/ml Levetiracetam : 20.83 mg/ml		4254
	Cefotaxime sodium : 200 mg/ml Levofloxacin : 5 mg/ml		1072
	Cefotaxime sodium : 10 mg/ml Lorazepam : 0.33 mg/ml		186
	Cefotaxime sodium : 20 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
	Cefotaxime sodium : 20 mg/ml Melphalan : 0.1 mg/ml		169
	Cefotaxime sodium : 100 mg/ml Meropenem : 50 mg/ml		4319
	Cefotaxime sodium Metronidazole		3594
	Cefotaxime sodium : 20 mg/ml Metronidazole : 5 mg/ml		1035
	Cefotaxime sodium : 10 mg/ml Metronidazole : 5 mg/ml		281
	Cefotaxime sodium : 20 mg/ml Midazolam hydrochloride : 1 mg/ml		176
	Cefotaxime sodium : 10 mg/ml Midazolam hydrochloride : 5 mg/ml		186
	Cefotaxime sodium : 40 mg/ml Morphine hydrochloride : 0,2 mg/ml		4832
	Cefotaxime sodium : 300 mg/ml		999
	Cefotaxime sodium : 20 mg/ml Morphine sulfate : 1 mg/ml		405
	Cefotaxime sodium N-acetylcysteine : 200 mg/ml		3766
	Cefotaxime sodium : 20 mg/ml Nalbuphine hydrochloride : 0,05 >> 0,33 mg/ml		4867
	Cefotaxime sodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Cefotaxime sodium : 40 mg/ml Nefopam : 0,16 mg/ml		4698
	Cefotaxime sodium Omeprazole sodium		3871
	Cefotaxime sodium Omeprazole sodium		3871
	Cefotaxime sodium : 20 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Cefotaxime sodium : 83.3 mg/ml Ornidazole : 31.25 mg/ml		4254
	Cefotaxime sodium : 100 mg/ml Oxycodone hydrochloride : 1 mg/ml		4842

		Cefotaxime sodium Pantoprazole sodium		2090
		Cefotaxime sodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Cefotaxime sodium : 20 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Cefotaxime sodium : 20 mg/ml Pentamidine isetionate : 3 mg/ml		275
		Cefotaxime sodium : 300 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Cefotaxime sodium : 100 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Cefotaxime sodium : 20 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Cefotaxime sodium : 25 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Cefotaxime sodium : 20 mg/ml Propofol : 10 mg/ml		300
		Cefotaxime sodium : 20 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Cefotaxime sodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Cefotaxime sodium : 20 mg/ml Sargramostim : 10 µg/ml		335
		Cefotaxime sodium : 100 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
		Cefotaxime sodium : 20 mg/ml Teniposide : 0.1 mg/ml		905
		Cefotaxime sodium : 83.3 mg/ml Thiamine hydrochloride : 0.4 mg/ml		4254
		Cefotaxime sodium : 100 mg/ml Thiopental sodium : 25 mg/ml		3767
		Cefotaxime sodium : 20 mg/ml Thiotepa : 1 mg/ml		249
		Cefotaxime sodium : 5 mg/ml Tinidazole : 2 mg/ml		2185
		Cefotaxime sodium : 50 & 200 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Cefotaxime sodium : 1 & 10 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Cefotaxime sodium : 1 >> 200 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674
		Cefotaxime sodium : 100 mg/ml Vancomycin hydrochloride : 5 & 12,5 mg/ml		260
		Cefotaxime sodium : 100 mg/ml Vancomycin hydrochloride : 25 & 30 mg/ml		260
		Cefotaxime sodium : 4 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Cefotaxime sodium : 20 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Route of administration



References

	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Journal	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Journal	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Journal	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Journal	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Journal	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.

260	Journal	Szof C, Walker PC. Incompatibility of cefotaxime sodium and vancomycin sulfate during Y-site administration. Am J Hosp Pharm 1993 ; 50: 2054, 2057.
275	Journal	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
281	Journal	Belliveau PP, Nightingale CH, Quintiliani R. Stability of cefotaxime sodium and metronidazole in 0.9% sodium chloride injection or in ready-to-use metronidazole bags. Am J Health-Syst Pharm 1995 ; 52: 1561-1563.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	Journal	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Journal	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
397	Journal	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
405	Journal	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
421	Journal	Foley PT, Bosso JA, Bair JN, Townsend RJ. Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures. Am J Hosp Pharm 1985 ; 42: 839-843.
472	Journal	Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.

496	Journal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
592	Journal	Barthes D, Fauconneau B, Martin JP, Courtois P. Effects of storage temperature and pH on the stability of cefotaxime in PVC bags. J Pharm Clin 1989 ; 8: 101-106.
593	Journal	Das Gupta V. Stability of cefotaxime sodium as determined by High-Performance Liquid Chromatography. J Pharm Sci 1984 ; 73: 565-567.
604	Manufacturer	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
939	Journal	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
999	Journal	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Journal	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Journal	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Journal	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	Journal	Saltzman CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1452	Journal	Muller HJ, Howe K, Frank C, Haker I. Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. Eur Hosp Pharm 2000 ; 6: 17-23.
1674	Journal	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.



























































1711	Journal	Das Gupta V. Stability of cefotaxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2002 ; 6: 234-236.
1712	Journal	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Journal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Journal	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2087	Journal	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Journal	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Journal	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2185	Journal	Guo P, Li X, Wan J, You A. Study on the compatibility of cefotaxime with tinidazole in glucose injection. J Pharm Biomed Anal 2007 ; 43: 1849-1853.
2374	Journal	CM Paap CM, Nahata MC. Stability of cefotaxime in two peritoneal dialysis solutions Am J Hosp Pharm 1990 ; 47: 147 - 150.
3012	Journal	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3125	Journal	Baker D S, Waldrop Bruce, Arnold John. Compatibility and Stability of Cefotaxime, Vancomycin, and Ciprofloxacin in Antibiotic Lock Solutions Containing Heparin. Int J Pharm Compound 2010 ; 14, 4: 346-349.
3201	Journal	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233-236.

3216	Journal	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3408	Journal	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Manufacturer	Cidomycin - Summary of product Characteristics. Sanofi 2011
3526	Manufacturer	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3549	Manufacturer	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3594	Manufacturer	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3643	Manufacturer	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Manufacturer	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3766	Journal	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Journal	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Journal	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3871	Poster	Soussi M.A, Soualah-alila R, jenene F, Lazreg O, Razgallah Khrouf M. Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ? Synpreph Congress Clermont Ferrand, France 2016
3964	Journal	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4254	Journal	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4268	Journal	D'Huart E, Vigneron J, Blaise F, Charmillon A, Demoré B. Physicochemical Stability of Cefotaxime Sodium in Polypropylene Syringes at High Concentrations for Intensive Care Units. Pharmaceutical Technology in Hospital Pharmacy 2019
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4538	Journal	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.

4603	Journal	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4698	Journal	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4742	Journal	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4832	Journal	Nilsson N, Storesund I, Tho I, Nezvalova□ Henriksen K. Co□ administration of drugs with parenteral nutrition in the neonatal intensive care unit—physical compatibility between three components. Eur J Pedia 2022 ; 181:2685–2693.
4837	Journal	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page□ Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4842	Journal	Souha H Y, Alka G, Yunmei S, Nicole E W, Sanjay G. Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors Drug Design Dev Ther 2024 Drug Design, Development
4845	Journal	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4867	Poster	Dazan D, Aït Taleb S, Laroyenne N, Hamam Y, Conreur L, Paoli-Lombardo R, Primas N, Lamy E, Castera-Ducros C, Curti C et al. Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. CSH (SNPHPU) Congress sept 2024 2024



Dictionary

 Antibiotic	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Glass
 NaCl 0,9% or Glucose 5%	 Light
 Hour	 Sodium chloride 0,9%
 Protect from light	 Not specified
 Polyvinyl chloride	 Day
 Glucose 5%	 Dianéal® PD1 1.5% glucose (Baxter)
 Dianéal® PD1 4.25% glucose (Baxter)	 Polyolefine
 Polypropylen Syringe	 Polyisoprene elastomer
 Stability of mixtures	 Solvent
 Compound	 Not specified
 Factors which affect stability	 Induces
 Enhanced stability	 Compatibility
 Immediate precipitation	 Incompatible
 Compatible	 Parenteral nutrition (with lipids)
 Precipitation after 1 hour	RL Ringer's lactate solution
 Chemical instability	 None
 Water for Injection	 Immediate turbidity
 Turbidity in 4 hours	 Parenteral nutrition (binary mixture)
 Unspecified incompatibility	 Precipitation after 4 hours
 Turbidity in one hour	 specific solvent
 Color change after 4 hours	 Route of administration
 Intravenous	 Intravenous infusion
 Intramuscular	 References
 Dictionary	